Want to see AU:MVF full AI Analyst Report?
Top Page
Monash IVF Group Ltd
(Sydney:MVF)
Select Model
Select Model
Rating:67Neutral
Price Target:
AU$0.74
▲(12.58% Upside)
Action:Reiterated
Date:11/25/25
Monash IVF Group Ltd's strong valuation metrics, including a low P/E ratio and high dividend yield, are the most significant strengths. However, the overbought technical indicators and weak cash flow position present notable risks. The absence of recent earnings call data and corporate events limits further insights.
Positive Factors
Revenue Growth
A 74.5% revenue increase reflects meaningful expansion in patient volumes or service mix, supporting long-term top-line momentum. Durable demand for fertility services and larger treatment throughput provide a base for reinvestment in clinics and labs across 2–6 months and beyond.
Negative Factors
Free Cash Flow Collapse
A near-total decline in free cash flow severely limits internal funding for capex, working capital and dividends. Over 2–6 months this raises reliance on external financing, constraining strategic investments and increasing vulnerability to funding cost swings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 74.5% revenue increase reflects meaningful expansion in patient volumes or service mix, supporting long-term top-line momentum. Durable demand for fertility services and larger treatment throughput provide a base for reinvestment in clinics and labs across 2–6 months and beyond.
Read all positive factors
Monash IVF Group Ltd (MVF) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$270.80M
Dividend Yield1.76%
Average Volume (3M)2.18M
Price to Earnings (P/E)17.9
Beta (1Y)1.24
Revenue Growth-0.03%
EPS GrowthN/A
CountryAU
Employees892
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.04
Shares Outstanding389,634,830
10 Day Avg. Volume1,374,502
30 Day Avg. Volume2,181,726
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.12
Price to Sales (P/S)1.01
P/FCF Ratio588.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.78Price Target Upside18.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$277.19M
Monash IVF Group Ltd Business Overview & Revenue Model
Company Description
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This inclu...
How the Company Makes Money
MVF primarily makes money by delivering fertility treatment cycles and associated clinical services to patients. The company’s revenue model is largely fee-for-service, with income generated from: (1) clinical fertility procedures and treatment pr...
Monash IVF Group Ltd Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 269.39M | 271.92M | 254.96M | 213.59M | 192.29M | 183.60M |
| Gross Profit | 75.88M | 90.31M | 85.50M | 63.41M | 57.22M | 57.66M |
| EBITDA | 54.19M | 53.01M | 10.78M | 48.49M | 43.16M | 51.21M |
| Net Income | 15.16M | 25.01M | -6.53M | 21.84M | 18.41M | 25.15M |
Balance Sheet | ||||||
| Total Assets | 510.21M | 492.61M | 508.47M | 421.89M | 387.10M | 356.17M |
| Cash, Cash Equivalents and Short-Term Investments | 8.14M | 9.43M | 11.33M | 8.01M | 7.87M | 8.76M |
| Total Debt | 281.81M | 180.31M | 135.37M | 100.04M | 77.23M | 45.99M |
| Total Liabilities | 252.26M | 242.19M | 261.81M | 146.82M | 117.20M | 87.73M |
| Stockholders Equity | 253.91M | 246.28M | 241.91M | 273.20M | 267.92M | 266.19M |
Cash Flow | ||||||
| Free Cash Flow | 9.23M | 468.00K | 31.70M | 10.16M | 19.51M | 33.30M |
| Operating Cash Flow | 23.21M | 12.90M | 52.52M | 37.95M | 31.28M | 43.25M |
| Investing Cash Flow | -18.93M | -17.43M | -38.80M | -40.51M | -15.16M | -11.21M |
| Financing Cash Flow | -1.33M | 2.67M | -10.39M | 1.51M | -17.02M | -38.35M |
Monash IVF Group Ltd Technical Analysis
Positive
0.66
Price Trends
0.70
Positive
0.71
Negative
0.71
Negative
Market Momentum
<0.01
Negative
53.03
Neutral
69.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Positive. The current price of 0.66 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.70, and below the 200-day MA of 0.71, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 69.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVF.
Monash IVF Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$11.06B | 20.15 | 6.39% | 4.99% | 13.14% | -2.73% | |
67 Neutral | AU$270.80M | 17.87 | 6.06% | 1.87% | -0.03% | ― | |
60 Neutral | AU$61.01M | 27.96 | 72.82% | ― | 22.56% | 19.47% | |
59 Neutral | AU$438.32M | 15.80 | 16.35% | 5.42% | 1.12% | -12.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$290.46M | -0.53 | -29.48% | ― | -12.15% | -2285.99% | |
43 Neutral | AU$5.67M | -0.43 | -184.98% | ― | ― | ― |
* Healthcare Sector Average
AU:MVF
Monash IVF Group Ltd
0.70
-0.11
-13.66%
AU:GTG
Genetic Technologies
0.04
0.00
0.00%
AU:HLS
Healius Limited
0.40
-0.41
-50.31%
AU:CTE
Cryosite Limited
1.25
0.50
66.67%
AU:SHL
Sonic Healthcare Limited
22.37
-4.84
-17.80%
AU:ACL
Australian Clinical Labs Ltd
2.35
-0.21
-8.17%
Monash IVF Group Ltd Corporate Events
Monash IVF Reports Lapse of 224,875 Unvested Performance Rights
Jul 10, 2026
Monash IVF Group Ltd has reported the lapse of 224,875 performance rights, designated under the ASX security code MVFAA, after the conditions attached to these rights were not met or became incapable of being satisfied as of 20 May 2026. The cessa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.